Announced
Financials
Sources
Tags
Pending
United States
biomarkers
Friendly
Biotechnology
Merger
immune monitoring
Private
Private Equity
Single Bidder
Synopsis
Caprion Biosciences and HistoGeneX agreed to merge. Financial terms were not disclosed. The new partnership creates a global leader in immune monitoring, protein characterization, and tissue pathology solutions for immunotherapy and drug development. The combined business will provide a full suite of immune monitoring and biomarker development services, from preclinical through late stage clinical trials and companion diagnostics, to biopharmaceutical organizations globally.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.